Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies

Sci Rep. 2014 Jun 5;4:5193. doi: 10.1038/srep05193.

Abstract

We developed a systematic algorithmic solution for quantitative drug sensitivity scoring (DSS), based on continuous modeling and integration of multiple dose-response relationships in high-throughput compound testing studies. Mathematical model estimation and continuous interpolation makes the scoring approach robust against sources of technical variability and widely applicable to various experimental settings, both in cancer cell line models and primary patient-derived cells. Here, we demonstrate its improved performance over other response parameters especially in a leukemia patient case study, where differential DSS between patient and control cells enabled identification of both cancer-selective drugs and drug-sensitive patient sub-groups, as well as dynamic monitoring of the response patterns and oncogenic driver signals during cancer progression and relapse in individual patient cells ex vivo. An open-source and easily extendable implementation of the DSS calculation is made freely available to support its tailored application to translating drug sensitivity testing results into clinically actionable treatment options.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Antineoplastic Agents / pharmacology*
  • Case-Control Studies
  • Drug Resistance, Neoplasm / drug effects*
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Models, Theoretical
  • Neoplasm Recurrence, Local / drug therapy*
  • Precision Medicine*
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents